KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Other Non-Current Liabilities (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Other Non-Current Liabilities data on record, last reported at $20.6 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 22.33% year-over-year to $20.6 million; the TTM value through Dec 2025 reached $20.6 million, up 22.33%, while the annual FY2025 figure was $20.6 million, 22.33% up from the prior year.
  • Other Non-Current Liabilities reached $20.6 million in Q4 2025 per PCRX's latest filing, up from $17.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $57.6 million in Q4 2021 and bottomed at $5.3 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $21.6 million, with a median of $17.8 million recorded in 2025.
  • The widest YoY moves for Other Non-Current Liabilities: up 968.97% in 2022, down 83.21% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $57.6 million in 2021, then plummeted by 83.21% to $9.7 million in 2022, then soared by 155.43% to $24.7 million in 2023, then tumbled by 31.91% to $16.8 million in 2024, then rose by 22.33% to $20.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $20.6 million in Q4 2025, $17.8 million in Q3 2025, and $17.2 million in Q2 2025.